📣 EYE CARE NEWS ROUND UP 👁 🔥 NEW FDA APPROVALS Iveric Bio, An Astellas company receives U.S FDA...
The Eyerising International Myopia Management Device has been introduced as a ground breaking solution to combat myopia effectively.
What does it do?
Using patented Repeated Low-Level-Red-Light (RLRL) therapy, it gently stimulates blood flow in the ocular fundus, addressing the root cause of myopia, sclera hypoxia, and controlling axial lengthening.
What is the process?
RLRL therapy has been proven in published clinical trials to dramatically reduce the progression of myopia by up to 87.7%.
What are the results?
Therapy involves looking into the device for 3 minutes of treatment, twice a day, 5 days per week, with a minimum of 4 hours between sessions. The device is controlled with a simple touchscreen and is suitable for children as young as 3 years of age with any level of myopia.
Did you know:
Myopia is predicted to affect 52% of the world’s population by 2050.😯
